ArticleBMC cancer2021

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.

Jaclyn M Beca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.